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Background: Efforts to improve end of life care (EoLC) have made tangible impacts on care in adults, including
enabling more people to die at their preferred place of death (PoD), usually home or hospices. Little is known how
the PoD in children and young people (CYP, ≤24 years) has changed over time, especially in the context of a series
of national initiatives for EoLC improvement since the late 1990s. To inform evidence-based policy-making and
service development, we evaluated the national trends of PoD and the associated factors in CYP who died with
cancer.
Methods: Population-based observational study in the National Health Service (NHS) England, 1993-2014. All
non-accidental CYP deaths with cancer (N = 12,774) were extracted from the death registration database of the
Office for National Statistics (ONS).
Results: Hospital deaths reduced from >50 to 45 %, hospice deaths were rare but more than doubled from 6 % in
1993–2000 to 13 % in 2005–2014, and home deaths fluctuated at around 40 %. Those aged 0–19 years were more
likely to die at home than young adults (adjusted proportion ratio (PRs): 1.23–1.62); haematological cancer patients or
those with 2+ comorbid conditions had higher chances of hospital death (PRs for home: 0.18–0.75, hospice: 0.04–0.37);
deprivation was associated with a reduced chance of home death (PRs: 0.76–0.84). The residential region affected
hospice but not home deaths. The variations of PoD by cause of death, comorbid conditions and deprivation slightly
decreased with time.
Conclusions: Hospitals and home were the main EoLC settings for CYP with cancer. Home death rates barely changed
in the past two decades; deaths in hospitals remained the most common but slightly shifted towards hospices. CYP
with haematological malignancy or with comorbid conditions had persistently high hospital deaths; these cases had
an even lower chance of deaths in hospices (50 %) than at home. There were deprivation- and area-related inequalities
in PoD which may need service- and/or policy-level intervention. The findings highlight a need for CYP specific
initiatives to enhance EoLC support and capacities both at home and in hospices.
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A “good death” as understood by many is one that occurs
at home or in a home-like environment (e.g., hospice) [1].
However, when it is weighted against the basic physical
needs, which are free of pain and other symptoms, to die in
one’s preferred place of death (PoD) becomes far less im-
portant [2]. Children and young people (CYP) with cancer
and their carers also rate the “physical comfort” as the top
concern [3, 4]. Quality end of life care (EoLC) encompasses
four dimensions of needs: physical, psychological, social
and spiritual, and should also extend the support to family
members throughout the dying process [5]. Unless these
needs, particular the symptom management, can be ad-
dressed at a consistently high standard across various care
settings, patients and their carers cannot meaningfully exer-
cise their choice for PoD. In fact, most deaths are still hap-
pening in the least preferred option – hospital [6–9]. In this
context, the PoD remains a useful indicator for population-
based EoLC needs and how the needs have been met.
A series of EoLC tools have been developed and sequen-
tially implemented in the United Kingdom since late
1990s, including the Gold Standard Framework, Preferred
Priorities for Care and the now phased out Liverpool Care
Pathway for the Dying Patient [10–12]. The NHS End of
Life Care Programme launched at the end of 2004 has con-
tributed significantly to the roll out of these programmes
[1, 13]. Although primarily targeted for adults, these tools
have also been adapted for use in CYP. From 2004, frame-
work and strategic documents specifically designed for
CYP were developed, in an attempt to raise the quality
standard of EoLC [14, 15]. At around the same time, paedi-
atric palliative care services in England received its largest
ever single investment (£48 millions) from the Big Lottery
Fund towards their nationwide development, aiming to in-
crease the provision of, and access to, hospice and
community-based support to children with cancer and
other life-threatening and life-limiting conditions [16].
Recent studies in England and in the States found a PoD
shift from hospitals to either home or hospices among
adults who died from cancer or dementia, corresponding
with the national EoLC improvement initiatives [7, 17, 18].
While to some extent overlapping with adults, CYP have
their distinct care needs and characteristics [19–21]. It is
essential to understand whether the primarily adult-
focused national efforts worked for CYP and how. It is
crucial for policy and service development. Two studies
examined the population-based PoD patterns in CYP and
found significant variation, but neither of them did so in
the changing context [22, 23.] This study aimed to
evaluate how the PoD and the determinants in CYP
with cancer changed over time. We chose to focus on
cancer as it is a leading non-accidental mortality in CYP
[24–26], but not currently optimally served by palliative
and EoLC service [19, 21].Methods
Study design and setting
A population-based study in the National Health Service
(NHS) England.
Data sources and study populations
Data were collected by the Office for National Statistics
(ONS) from all death registrations in England, 1993–2014.
By law in England, a death must be registered within
5 days, unless it becomes the subject of a coroner’s
inquiry. The underlying cause of death (CoD) was re-
corded in the database using the 9th (1993–2000) or 10th
(2001–2014) edition of International Classification of Dis-
eases (ICD-9, ICD-10) codes. All non-external cause of
deaths (ICD-9: E codes; ICD-10: T79-T98, Y35–36 &
Y40–Y98) that occurred before the age of 24 years, with
cancer as the underlying or contributing CoD (ICD-10:
C00–C97; ICD-9: 140–209), were included for this study.
Variables
The study outcome – PoD, was grouped into four cat-
egories: hospital, home, hospice, and elsewhere. Hospice,
in this context, refers to a dedicated unit with in-patient
beds, staffed by specialists in palliative care, and is usu-
ally freestanding from hospitals. Admission to hospice is
not restricted to those at the EoL, CYP are often admit-
ted for symptom control, or other reasons (e.g., respite
care). Hospices are not for profit and do not charge for
admission. Explanatory variables included: age at death
(<1, 1–4, 5–9, 10–14, 15–19, 20–24), gender (male, fe-
male), the underlying cause of death (See Table 1 for
ICD-9/10 codes) – the number of contributing cause of
deaths (defined as diseases or injuries that contributed to
the fatal outcome), year of death, the index of deprivation,
the rural/urban indicator and the region (defined by Clin-
ical Senate, 2013) [27] of the deceased residential address.
Age was analysed as an ordered categorical variable rather
than a continuous variable to facilitate interpretation and
comparison with the other studies. The deprivation - an
indicator of socioeconomic position [28] - was measured
by the lower super output area (LSOA) quintile of the in-
come deprivation affecting children index (IDACI), where
1 =most deprived and 5 = least deprived. The IDACI is
calculated by the Office of the Deputy Prime Minister and
measures in a local area the proportion of children under
the age of 16 that live in low income households. The local
areas for which the index is calculated are LSOA. A LSOA
is a low-level geographic area that is designed for report-
ing small area statistics in England and Wales. There are
32,482 LSOAs in England; each area has a minimum
population size of 1,000 and an average of 1,500. The
rural/urban settlement was classified using the 2011 Cen-
sus data at the level of LSOA. We used IDACI 2001,
IDACI 2004 and IDACI 2007 to map the residential area-
Table 1 ICD-9 & 10 codes for underlying causes of death classification
Group Underlying cause of death* ICD-10 codes ICD-9 codes
1 Leukaemia: ALL C91.0 204.0
2 Leukaemia: AML C92.0, C92.4, C92.5, C92.6, C92.8, C93.0, C94.0, C94.2 205.0, 206.0, 207.0, 207.2
3 Leukaemia: other C91-C95 excluding above 204–208 excluding above
4 Lymphomas: Hodgkin’s C81 201
5 Lymphomas: non-Hodgkin’s C82-C86 200, 202
6 Myeloma C90 203
7 Brain, other CNS & Intracranial tumours C70-C72, C75.1-C75.3, D32-D33,
D35.2-D35.4, D42-D43, D44.3-D44.5
191–192, 194.3–194.4, 225, 227.3–227.4,
237.0, 237.1, 237.5, 237.6, 239.6
8 Connective tissue cancer C46, C47, C49 171
9 Bone sarcoma C40-C41 170
10 Renal tumours C64 189.0
11 Hepatic tumours C22 155
12 Adrenal tumors including neuroblastoma C74 194.0
13 Retinoblastomas C69.2 190.5
14 Other malignant C00-C97 excluding all above C codes 140–209 excluding above
15 Other neoplasm D00-D48 excluding above D codes 210–239 excluding above
16 Non-cancer A00-B99, D50-R99 000–139, 240–799
*Underlying causes of death grouping: Leukemia: 1–3; Lymphomas & other haematological: 4–6; Brain & other CNS tumors: 7; Bone & connective tissue: 8–9;
Renal/Liver/Adrenal including neuroblastoma: 10–12; Other malignant: 13–15; Non-cancer: 16
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2000, 2001–2004, 2005–2014, respectively. The study
period was divided into three intervals in order to exam-
ine changing patterns. The division took into consider-
ation the launch, implementation and roll-out of several
national initiatives around 2004/2005 for improving EoLC
[1, 13]; and also the ONS’s ICD coding system changing
from the ICD-9 to the ICD-10 in 2001.
Statistical analysis
Data was first checked for errors and missing values; if
the missing data was less than 5 %, the records were
deleted using the list-wise approach [29]. Data was de-
scribed using frequency, proportion and 95 % confidence
interval (CI). The time trend in proportion of CYP can-
cer deaths in four PoDs was evaluated and tested using
Tobit regression models, weighted by the total number
of CYP deaths and the number of CYP cancer deaths.
The proportion was age- and sex-standardised using the
1993’s structure. The year of death was treated as a con-
tinuous variable. The regional variation was visualised
with geographical maps.
Modified Poisson regression models were used to evalu-
ate the factors independently associated with PoD. Two
sets of models were constructed separately for the three
time periods: home (1) versus hospital (0), and hospice (1)
versus hospital (0). All explanatory variables were kept in
the model. To ensure statistical efficiency, we categorised
age into three groups: 0–14, 15–19, 20–24. The strength of
association was measured by the proportion ratio (PR) – ameasure of relative risk (RR), estimated from the period-
specific models.
Possible two-way interaction effect between factors
were explored and tested, using the likelihood ratio test
of nested reduced models with and without the inter-
action terms. The collinearity was evaluated with the
condition index (CI). A CI value greater than 30 indi-
cates the presence of collinearity. If two factors were
found significantly associated with each other, sensitivity
analysis would be carried out by running separate
models omitting one of the concerned variables. The
resulting parameter estimates would then be compared
to those from the main analysis models.
All statistical tests were two-sided; statistical signifi-
cance is defined as p < 0.05. All analyses were performed
using the SAS 9.4 (SAS Institute Inc, Cary, North Carolina).
The GIS mapping was completed with R version 3.1.2 soft-
ware (www.r-project.org) and R Studio Version 0.98.1091.
Results
Demographic and clinical details, information on
potential confounders
Between 1993 and 2014 in England, 12,774 CYP died
with cancer as an underlying or contributory cause of
death, accounting for 18.7 % of non-accidental causes of
CYP deaths. The proportion of cancer deaths increased
from 18 to 25 %. The number of CYP cancer deaths fell
36 % from 729 in 1993 to 470 in 2014 (Fig. 1). Table 2
shows the demographic and clinical characteristics of
the study population. Proportions of cancer deaths by
Fig. 1 Proportion of place of death and total number of deaths in children and young people who died with cancer, England 1993–2014
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aged between 15–24 years. More males than females died
from cancer. Haematological malignancies (Leukaemia,
Lymphoma & other haematological cancers, N = 2580)
comprised over 30 % of CYP cancer deaths prior to 2005,
but its proportion reduced over time to the same level as
brain & CNS cancer (27 %, N = 1369) in 2005–2014. A
small proportion (3.2–4.2 %) of CYP with cancer died
from a non-cancer cause, nearly half (45 %) of them had a
haematological cancer mentioned on their death certifi-
cates. Around 10 % of CYP cancer deaths had three or
more contributing causes of death. There was a small pro-
portion increase of CYP deaths with cancer, living in the
most deprived area (44 to 46 %). Most CYP dying with
cancer (~84 %) lived in an urban area (Table 2).
Place of death and the time trends
The proportion of hospital deaths fell from over 50 %
before 2005 to 45 % (95 % CI: 44–46 %) afterwards;
deaths at home did not change much and fluctuated at
around 40 %. The hospice deaths doubled from 4 % (95 %
CI: 3–6 %) in 1993, to around 10 % (n = 50) up until 2008,
followed by a further rise to 14 % (n = 73) in 2009 and
remained constant at around that level since then (Fig. 1).
Both the relative (0.4 % per year) and absolute (3 per year)
increase of number of deaths at hospices, with the adjust-
ment of the total number of CYP cancer deaths and CYP
deaths (p < 0.001), were statistically significant. Most of
the time hospitals were the most prevalent PoD. In 2007/
2008, there was a shift in place of death: hospital deaths
decreased and both home and hospice deaths in-
creased. The percentage of hospital and home deaths
were similar between 2008 and 2012, after which
there was a shift to more hospital and fewer home
deaths, with hospital again becoming the most preva-
lent place for CYP with cancer spending their last
moments of life (Fig. 1).Spatio-temporal variations in place of death
The PoD varied considerably by region, but showed an
overall consistent trend for a relative reduction in hos-
pital deaths, an increase in hospice deaths and little
changes in at-home deaths from the earliest to the latest
periods (Fig. 2, Appendix Figures 3 and 4). In 2005–
2014 (Fig. 2), London had the highest proportion of hos-
pital deaths (56 %, 95 % CI: 52–59 %) and lowest home
deaths (31 %; 95 % CI: 28–34 %); in contrast to Wessex,
where hospital deaths were the lowest (33 %; 95 % CI:
26–39 %) and home deaths the highest (56 %; 95 % CI:
49–63 %). Hospice deaths in North East, north Cumbria,
and the Hambleton & Richmondshire districts of North
Yorks and in Wessex (8 %; 95 % CI:5–12 %) were the
lowest in the country; Thames Valley, South West and
South East Coast (range:14–23 %) had the highest pro-
portion of CYP with cancer who died in a hospice in
England.
Factors associated with place of death
Multivariable modelling results for factors associated
with PoD are presented in Tables 3 and 4. In all three
periods, age, CoD, number of contributing CoDs, and
region were independently associated with the PoD
(P < 0.001). Compared to young adults (20–24), those
aged 0–19 years were more likely to die at home
(PRs: 1.23–1.62) and less likely to die in a hospice
(PRs: 0.41–0.71) than young adults, but the difference in
hospice deaths was getting smaller (PRs: 0.89–0.92) and
no longer significant in 2005–2014 (P = 0.42).
Both underlying cause of death (CoD) and the number
of contributing CoDs were strong determinants of PoD.
Compared to those who died from Brain and CNS tu-
mours, patients with a haematological cancer or non-
cancer as a underlying CoD had a significantly lower chance
of dying at home (haematological cancer PRs:0.58–0.75;
non-cancer PRs:0.31–0.57) or at a hospice (haematological
Table 2 Demographical and clinical characteristics of children
and young people who died with cancer, England 1993–2014
(N = 12,774)
Variable Value Year of death
1993–2000 2001–2004 2005–2014
Total – 5187 2431 5156
Average/year – 649 608 517
Age <1 162(3.1) 63(2.6) 152(2.9)
01–04 736(14.2) 325(13.4) 722(14.0)
05–09 887(17.1) 377(15.5) 785(15.2)
10–14 808(15.6) 411(16.9) 743(14.4)
15–19 1062(20.5) 574(23.6) 1169(22.7)
20–24 1532(29.5) 681(28.0) 1585(30.7)
Gender Female 2193(42.3) 1059(43.6) 2244(43.5)
Male 2994(57.7) 1372(56.4) 2912(56.5)
Underlying
cause of death
















Non-cancer 220(4.2) 85(3.5) 165(3.2)
N. contributing
CoDs
0 2476(47.7) 1209(49.7) 2757(53.5)
1 1703(32.8) 680(28.0) 1300(25.2)
2 648(12.5) 311(12.8) 605(11.7)
3+ 360(6.9) 231(9.5) 494(9.6)
IDACI quintile Most deprived 1252(24.1) 585(24.1) 1317(25.5)
2 1033(19.9) 494(20.3) 1064(20.6)
3 1003(19.3) 451(18.6) 1002(19.4)
4 909(17.5) 445(18.3) 879(17.0)
Least deprived 990(19.1) 456(18.8) 894(17.3)
Settlement Urban 4345(83.8) 2031(83.5) 4326(83.9)






East Midlands 463(8.9) 209(8.6) 467(9.1)






London 717(13.8) 383(15.8) 847(16.4)
Table 2 Demographical and clinical characteristics of children
and young people who died with cancer, England 1993–2014








South East Coast 419(8.1) 206(8.5) 424(8.2)
South West 438(8.4) 192(7.9) 436(8.5)
Thames Valley 172(3.3) 85(3.5) 176(3.4)
Wessex 280(5.4) 108(4.4) 221(4.3)




Place of death Hospital 2656(51.2) 1271(52.3) 2317(44.9)
Home 2129(41.0) 896(36.9) 2069(40.1)
Hospice 307(5.9) 212(8.7) 660(12.8)
Elsewhere 95(1.8) 52(2.1) 110(2.1)
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lihood of death at home or in a hospice was inversely asso-
ciated with the number of contributing CoDs. The chance
of home death in CYPs with two or more contributing
CoDs was less than half of that for those with no contribut-
ing CoD (PRs 0.18–0.48); the effect of contributing CoDs
was more pronounced for hospice death (PRs:0.04–0.29).
The inequality in PoD by CoD or by contributing CoDs
showed no sign of narrowing down.
Residents of the two most deprived quintile areas had
a reduced chance of death at home (PRs: 0.76–0.90); no
disparities in home deaths were observed from the third
to the highest quintile. The gap of the home deaths be-
tween the deprivation quintiles slightly widened during
the study period. The chance of hospice death did not
vary with deprivation. The geographical variation was
persistent after controlling the potential confounding
variables. Gender and type of settlement (rural/urban)
were not related to where a CYP with cancer died.
There was significant interaction between the CoD and
the number of CoDs in home death models (p < 0.001)
but the condition index (CI) did not indicate the presence
of significant collinearity (intercept adjusted CIs range:
1.11–1.17). However, the PR estimations from the sensitiv-
ity analyses with one of these two factors omitted from
the models were only slightly different from those from
the main analysis (Appendix Tables 5, 6, 7, 8).
Discussion
This is the first population-based evaluation of the PoD
and its determinants in CYP in the context of national
EoLC policies and initiatives. We found that despite a
Fig. 2 Geographical variations in place of death in children and young people who died with cancer, England 2005–2014. 1: Cheshire & Merseyside; 2:
East Midlands; 3: East of England; 4: Greater Manchester, Lancashire & south Cumbria; 5: London; 6: North East, north Cumbria and the Hambleton &
Richmondshire districts of North Yorkshire; 7: South East Coast; 8: South West; 9: Thames Valley; 10: Wessex; 11: West Midlands; 12: Yorkshire & the Humber
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rate barely changed in the past two decades. In England,
palliative care for children is typically provided at home,
with support from a hospital-based oncology team coor-
dinated by paediatric oncology outreach nurse specialists
(POONS) [30]. This care model is effective in enabling
home death [17, 31]. In theory, a fallen mortality may
free up some home care resources to support more
home deaths. However, the benefit appeared not to be
transferred. A study from Taiwan using administrative
data found that the EoLC in paediatric cancer patients
was aggressive with heavy use of life sustaining and cura-
tive treatments, and lack of support of deaths at home
[32]. Future studies need to elucidate the roles of these
factors in where children and young people die. Com-
pared to adults, the PoD change and the reduction in
inequality in CYP appeared to be of a lesser degree with
a time delay (e.g., until 2008). A recent study using
Medicare data demonstrated that the EoLC needs in the
young population may be different from those of adults
[33]. Our data suggests the inadequacy of adult focused
policy interventions for CYP, highlights a need for CYP-
specific national initiatives that improve PEoLC care
support at home.
Hospitals remained the most common PoD for CYP
with cancer, around nearly half of the deaths occurred
there. There was a tendency of PoD shifting from hospi-
tals towards hospices. The shifting coincided with the
landmark launch of the national EoLC programme in
Nov 2004 and subsequent national efforts [13]. The PoD
in adults with cancer during the same period in England
shifted towards both home and hospices with more pro-
nounced effects on home deaths [17]. The PoD shifting
outside hospitals is consistent with findings from other
countries [34–36]. The hospice deaths increased but were
still rather low in most England’s regions, ranging from
under 10 % to around 20 %. Hospices have been mostlyused as a respite service in the UK. Their potential as a
great alternative to hospital in meeting the needs of man-
aging physical symptoms has not yet been fully exploited.
Future research needs to focus on how to increase and ex-
pand the use of hospice services.
Although the chance of home and hospice deaths for
CYPs with most cancers improved though slowly over
time, deaths of those with haematological cancer still pre-
dominantly (~70 %) took place in hospitals. There was lit-
tle change in this proportion over time, similar to what’s
seen in adults [17]. Haematological cancers accounted for
nearly 1 in 3 CYP cancer deaths. Over half of the non-
cancer deaths had a haematological cancer as a contribut-
ing CoD. This is consistent with a previous systematic re-
view and meta-analysis [37]. The review also highlighted
that the reasons for the high hospital deaths in haematol-
ogy patients are not yet clear, but likely to be multidimen-
sional and complex. The number of CoDs has been used
as a proxy measure of comorbidities [38, 39], which, in
turn, translates into the care management complexity at
the end of life [40]. The CYP deaths with more contribut-
ing CoDs were less likely to occur at home or in a hospice.
While these results should be interpreted with caution as
the recording practice may vary by location of death, con-
stantly improving cancer survival and increasing comor-
bidities among cancer survivors are bound to make EoLC
management more challenging [41, 42].
Given that home and hospices are preferred and in-
creasingly important for CYP cancer patients to spend
their last moments of life, the healthcare system should
be better equipped to meet such needs. Surprisingly,
compared to those with no contributing CoDs, a patient
with two or more contributing CoDs had 80 % lower
chance of dying in a hospice, even lower than that of
home deaths. It appears that when it comes to cases
with comorbid conditions, hospice as a dedicated EoLC
facility does not seem to be more advantageous than
Table 3 Factors associated * with home deaths (versus hospital deaths) in children and young people with cancer, England 1993–2014
(N = 12,774)
Variable Value Year of death
1993–2000 2001–2004 2005–2014
Age(ref: 20–24) 0–14 1.62(1.44 to 1.82) 1.51(1.26 to 1.82) 1.34(1.19 to 1.50)
15–19 1.23(1.07 to 1.41) 1.39(1.14 to 1.71) 1.28(1.12 to 1.45)
Gender Male vs female 1.07(0.98 to 1.16) 1.04(0.91 to 1.19) 1.06(0.97 to 1.15)
Underlying cause of death
(ref: Brain & CNS)
Leukaemia 0.72(0.63 to 0.82) 0.73(0.60 to 0.90) 0.58(0.51 to 0.68)
Lymphoma & other haematology 0.75(0.61 to 0.91) 0.65(0.47 to 0.88) 0.60(0.48 to 0.74)
Bone & connective 1.39(1.21 to 1.59) 1.29(1.06 to 1.57) 1.07(0.95 to 1.21)
Renal/Liver/Adrenal including neuroblastoma 1.20(1.04 to 1.39) 1.27(1.02 to 1.57) 0.93(0.80 to 1.07)
Other malignant 1.08(0.94 to 1.24) 0.90(0.71 to 1.14) 0.90(0.78 to 1.03)
Non-cancer 0.31(0.19 to 0.49) 0.33(0.15 to 0.75) 0.57(0.37 to 0.87)
N. contributing CoDs (ref: 0) 1 0.82(0.75 to 0.91) 0.81(0.70 to 0.94) 0.82(0.74 to 0.91)
2 0.48(0.40 to 0.57) 0.33(0.24 to 0.45) 0.40(0.33 to 0.48)
3+ 0.26(0.19 to 0.36) 0.18(0.11 to 0.29) 0.18(0.13 to 0.25)
Deprivation (ref: 5 least deprived) 1(most deprived) 0.85(0.74 to 0.97) 0.77(0.61 to 0.96) 0.76(0.66 to 0.88)
2 0.90(0.78 to 1.03) 0.97(0.78 to 1.20) 0.83(0.72 to 0.96)
3 0.95(0.84 to 1.09) 1.02(0.82 to 1.25) 1.00(0.87 to 1.14)
4 0.97(0.84 to 1.11) 1.09(0.89 to 1.34) 0.99(0.86 to 1.13)
Rural/urban indicator Rural vs Urban 1.07(0.95 to 1.20) 1.08(0.90 to 1.29) 1.00(0.89 to 1.13)
SCN region (ref: London) Cheshire & Merseyside 1.17(0.93 to 1.48) 1.19(0.84 to 1.67) 1.01(0.78 to 1.30)
East Midlands 1.03(0.84 to 1.25) 1.03(0.77 to 1.38) 1.09(0.90 to 1.32)
East of England 1.27(1.06 to 1.52) 1.07(0.82 to 1.41) 1.26(1.06 to 1.51)
Greater Manchester, Lancashire and south Cumbria 1.10(0.90 to 1.34) 0.94(0.69 to 1.27) 1.07(0.87 to 1.32)
North East, north Cumbria, and the Hambleton &
Richmondshire districts of North Yorkshire
1.23(1.01 to 1.52) 1.42(1.05 to 1.93) 1.41(1.14 to 1.73)
South East Coast 1.06(0.87 to 1.30) 1.21(0.91 to 1.61) 1.26(1.04 to 1.53)
South West 1.24(1.02 to 1.50) 1.03(0.76 to 1.41) 1.28(1.06 to 1.56)
Thames Valley 1.21(0.93 to 1.57) 1.14(0.77 to 1.68) 1.09(0.82 to 1.45)
Wessex 1.25(1.01 to 1.54) 1.17(0.84 to 1.64) 1.43(1.15 to 1.78)
West Midlands 1.18(0.99 to 1.41) 0.86(0.63 to 1.17) 1.23(1.03 to 1.48)
Yorkshire & The Humber 0.94(0.78 to 1.14) 1.08(0.82 to 1.44) 1.12(0.93 to 1.35)
*The association is measured by proportion ratios(PRs) and 95 % confidence intervals. PR > 1 indicates a higher probability of home deaths, <1 lower chance of
home deaths, PR = 1 indicates no association. The PRs were derived from modified Poisson regression model, adjusting for the listed variables, the number of CYP
deaths and the number of CYP cancer deaths at SCN region level
Gao et al. BMC Cancer  (2016) 16:727 Page 7 of 15people’s own home. Further investigations to the reasons
are needed. The level of deprivation was related to lower
chances of home deaths but not hospice deaths, the in-
equality gap showed little sign of closing up. The wide
regional variations in PoD are worth exploring in depth,
as a better understanding of these variations may reveal
important clues for local practices, policies and service
configurations that facilitate and enable home or hospice
death.
It is worth noting that these findings were observed in
the background of a relative increase (from 18 to 25 %)
in CYP cancer deaths, partly due to the mortalityreduction in competing causes of death (e.g., diabetes,
asthma) [43]. This trend is likely to continue, given the
rise of the cancer incidence [44]. Our findings suggest
that even in the traditionally and relatively better served
disease group – cancer [45], the end of life care for CYP
is suboptimal. It is even more unfortunate, as it hap-
pened in a country ranked consistently the best in the
world for its quality of death [46]. There is a pressing
need for national and international actions to improve
end of life care for this neglected CYP population.
This study has several limitations. We did not have in-
formation regarding care and transition of the care
Table 4 Factors associated * with hospice deaths (versus hospital deaths) in children and young people with cancer, England
1993–2014(N = 12,774)
Variable Value Year of death
1993–2000 2001–2004 2005–2014
Age(ref: 20–24) 0–14 0.41(0.31 to 0.54) 0.71(0.51 to 0.98) 0.91(0.76 to 1.10)
15–19 0.56(0.40 to 0.76) 0.63(0.42 to 0.93) 0.92(0.74 to 1.14)
Gender Male vs female 0.86(0.68 to 1.07) 0.86(0.65 to 1.13) 0.92(0.79 to 1.08)
Underlying cause of death
(ref: Brain & CNS)
Leukaemia 0.26(0.18 to 0.39) 0.35(0.22 to 0.57) 0.26(0.19 to 0.35)
Lymphoma & other haematology 0.29(0.17 to 0.48) 0.18(0.08 to 0.43) 0.36(0.24 to 0.53)
Bone & connective 0.93(0.65 to 1.32) 0.98(0.66 to 1.44) 0.79(0.63 to 1.00)
Renal/Liver/Adrenal including neuroblastoma 0.76(0.46 to 1.24) 0.86(0.49 to 1.48) 0.53(0.39 to 0.73)
Other malignant 0.77(0.57 to 1.05) 0.79(0.53 to 1.17) 0.82(0.67 to 1.02)
Non-cancer 0.21(0.06 to 0.67) 0.14(0.02 to 1.03) 0.11(0.03 to 0.46)
N. contributing CoDs (ref: 0) 1 0.81(0.64 to 1.03) 0.53(0.37 to 0.75) 0.62(0.51 to 0.75)
2 0.29(0.17 to 0.49) 0.25(0.13 to 0.46) 0.22(0.15 to 0.32)
3+ 0.04(0.01 to 0.26) 0.15(0.06 to 0.36) 0.16(0.10 to 0.26)
Deprivation (ref: 5 least deprived) 1(most deprived) 0.99(0.71 to 1.39) 0.82(0.52 to 1.29) 0.91(0.71 to 1.18)
2 0.92(0.64 to 1.31) 1.06(0.68 to 1.64) 0.84(0.65 to 1.09)
3 0.72(0.49 to 1.05) 1.15(0.74 to 1.78) 1.00(0.78 to 1.29)
4 0.76(0.52 to 1.12) 0.97(0.61 to 1.55) 0.92(0.70 to 1.20)
Rural/Urban indicator Rural vs Urban 0.99(0.70 to 1.40) 1.08(0.73 to 1.60) 0.96(0.77 to 1.21)
SCN region (ref: London) Cheshire & Merseyside 2.06(1.10 to 3.85) 1.18(0.55 to 2.52) 0.91(0.59 to 1.41)
East Midlands 0.98(0.51 to 1.90) 0.69(0.33 to 1.42) 0.97(0.69 to 1.38)
East of England 1.51(0.84 to 2.73) 1.57(0.91 to 2.69) 1.24(0.91 to 1.70)
Greater Manchester, Lancashire and south Cumbria 3.43(2.12 to 5.58) 1.55(0.92 to 2.63) 1.06(0.76 to 1.48)
North East, north Cumbria, and the Hambleton
& Richmondshire districts of North Yorkshire
1.04(0.48 to 2.26) 0.66(0.23 to 1.90) 0.96(0.60 to 1.54)
South East Coast 2.46(1.42 to 4.27) 1.62(0.89 to 2.97) 1.38(0.99 to 1.92)
South West 2.27(1.30 to 3.97) 1.38(0.75 to 2.53) 1.83(1.35 to 2.47)
Thames Valley 1.74(0.77 to 3.93) 0.85(0.34 to 2.10) 1.71(1.18 to 2.48)
Wessex 1.22(0.58 to 2.59) 0.52(0.18 to 1.53) 0.99(0.59 to 1.68)
West Midlands 2.05(1.22 to 3.42) 0.88(0.48 to 1.61) 1.13(0.82 to 1.54)
Yorkshire & The Humber 2.44(1.49 to 4.02) 1.75(1.03 to 2.98) 1.14(0.83 to 1.56)
*The association is measured by proportion ratios(PRs) and 95 % confidence intervals. PR > 1 indicates a higher probability of hospice deaths, <1 lower chance of
hospice deaths, PR = 1 indicates no association. The PRs were derived from modified Poisson regression model, adjusting for the listed variables, the number of
CYP deaths and the number of CYP cancer deaths at SCN region level
Gao et al. BMC Cancer  (2016) 16:727 Page 8 of 15settings; the death certificate data only contains an indi-
vidual’s final PoD. Even if a patient was admitted to a
hospital in the last minute and died there, the PoD will
be recorded as the hospital. There is evidence that pre-
ferred PoD may differ from preferred place of care25. We
should also note that we did not have information on
preferences of the patient and family members, or indica-
tors for clinical appropriateness of PoD. Nevertheless, as a
patient and/or their carer’s preference for where to die is
highly dependent on the level of care support one can get
in a specific setting [2, 47], the PoD is still a useful indica-
tor for EoLC needs and to what extent the need has been
met.Conclusions
Hospitals and home were the main EoLC setting for CYP
with cancer. The home death rate (~40 %) barely changed
in the past two decades, and deaths in hospital remained
the most common but slightly shifted towards hospices.
CYP with haematological malignancy and with comorbid
conditions had persistently high hospital deaths; the
chance of these cases with deaths in hospices was even
lower than at home. There were deprivation- and area-
related inequalities in PoD which may need service-level
change and/or policy-level intervention. The findings
highlight a need for CYP specific initiatives to enhance
EoLC support and capacities at home and in hospices.
Gao et al. BMC Cancer  (2016) 16:727 Page 9 of 15AppendixFig. 3 Geographical variations in place of death in children and young people who died with cancer, England 2001─2004. 1: Cheshire
& Merseyside; 2: East Midlands; 3: East of England; 4: Greater Manchester, Lancashire & South Cumbria; 5: London; 6: North East, North
Cumbria and the Hambleton & Richmondshire districts of North Yorkshire; 7: South East Coast; 8: South West; 9: Thames Valley; 10: Wessex; 11: West
Midlands; 12: Yorkshire & the Humber
Fig. 4 Geographical variations in place of death in children and young people who died with cancer, England 1993─2000. 1: Cheshire
& Merseyside; 2: East Midlands; 3: East of England; 4: Greater Manchester, Lancashire & South Cumbria; 5: London; 6: North East, North
Cumbria and the Hambleton & Richmondshire districts of North Yorkshire; 7: South East Coast; 8: South West; 9: Thames Valley; 10: Wessex; 11: West
Midlands; 12: Yorkshire & the Humber
Table 5 Factors associated * with home death(versus hospital death) in children and young people with cancer, England
1993–2014(N = 12,774)
Variable Value Year of death
1993–2000 2001–2004 2005–2014
Age(ref: 20–24) 0–14 1.64(1.46 to 1.84) 1.47(1.23 to 1.77) 1.34(1.19 to 1.50)
15–19 1.23(1.07 to 1.42) 1.33(1.09 to 1.63) 1.24(1.10 to 1.41)
Gender Male vs female 1.07(0.98 to 1.17) 1.06(0.93 to 1.21) 1.06(0.98 to 1.16)
Underlying cause of death
(ref: Brain & CNS)
Leukaemia 0.65(0.57 to 0.74) 0.60(0.49 to 0.74) 0.47(0.41 to 0.55)
Lymphoma & other haematology 0.71(0.58 to 0.86) 0.59(0.44 to 0.81) 0.52(0.42 to 0.65)
Bone & connective 1.33(1.16 to 1.52) 1.27(1.04 to 1.54) 1.08(0.96 to 1.23)
Renal/Liver/Adrenal including neuroblastoma 1.18(1.02 to 1.36) 1.31(1.06 to 1.62) 0.92(0.79 to 1.06)
Other malignant 1.02(0.89 to 1.17) 0.79(0.63 to 1.00) 0.83(0.72 to 0.95)
Non-cancer 0.18(0.11 to 0.28) 0.15(0.07 to 0.34) 0.26(0.18 to 0.40)
Deprivation (ref: 5 least deprived) 1(most deprived) 0.83(0.73 to 0.96) 0.78(0.62 to 0.97) 0.72(0.63 to 0.84)
2 0.88(0.76 to 1.01) 0.98(0.79 to 1.21) 0.81(0.70 to 0.93)
3 0.94(0.83 to 1.08) 1.02(0.82 to 1.25) 0.98(0.85 to 1.12)
4 0.95(0.83 to 1.08) 1.12(0.91 to 1.37) 0.99(0.87 to 1.14)
Rural/urban indicator Rural vs Urban 1.07(0.95 to 1.20) 1.08(0.90 to 1.28) 1.03(0.91 to 1.15)
SCN region (ref: London) Cheshire & Merseyside 1.19(0.95 to 1.50) 1.27(0.90 to 1.79) 1.04(0.81 to 1.34)
East Midlands 1.07(0.88 to 1.30) 1.10(0.82 to 1.47) 1.12(0.92 to 1.35)
East of England 1.30(1.08 to 1.56) 1.08(0.82 to 1.42) 1.26(1.05 to 1.50)
Greater Manchester, Lancashire and south Cumbria 1.15(0.95 to 1.41) 0.96(0.71 to 1.30) 1.07(0.87 to 1.31)
North East, north Cumbria, and the Hambleton &
Richmondshire districts of North Yorkshire
1.29(1.05 to 1.59) 1.41(1.04 to 1.91) 1.48(1.20 to 1.83)
South East Coast 1.11(0.91 to 1.36) 1.22(0.92 to 1.62) 1.27(1.05 to 1.54)
South West 1.30(1.07 to 1.57) 1.04(0.77 to 1.42) 1.30(1.07 to 1.58)
Thames Valley 1.28(0.99 to 1.66) 1.15(0.78 to 1.69) 1.11(0.84 to 1.48)
Wessex 1.35(1.09 to 1.67) 1.19(0.85 to 1.66) 1.48(1.19 to 1.84)
West Midlands 1.21(1.01 to 1.44) 0.84(0.61 to 1.14) 1.22(1.02 to 1.46)
Yorkshire & The Humber 0.94(0.78 to 1.15) 1.07(0.81 to 1.42) 1.17(0.97 to 1.41)
*The association is measured by proportion ratios(PRs) and 95 % confidence intervals. PR > 1 indicates a higher probability of home death, <1 lower chance of
home death, PR = 1 indicates no association. The PRs were derived from modified Poisson regression model, adjusting for the listed variables in the main analysis
but with the omission of the number of contributing CoDs, the number of CYP deaths and the number of CYP cancer deaths at SCN region level
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Table 6 Factors associated * with home death(versus hospital death) in children and young people with cancer, England
1993–2014(N = 12,774)
Variable Value Year of death
1993–2000 2001–2004 2005–2014
Age(ref: 20–24) 0–14 1.62(1.45 to 1.80) 1.58(1.33 to 1.88) 1.37(1.23 to 1.53)
15–19 1.22(1.06 to 1.40) 1.45(1.19 to 1.78) 1.30(1.15 to 1.48)
Gender Male vs female 1.05(0.97 to 1.15) 1.01(0.89 to 1.16) 1.04(0.96 to 1.14)
N. contributing CoDs (ref: 0) 1 0.85(0.77 to 0.93) 0.80(0.69 to 0.93) 0.81(0.73 to 0.89)
2 0.42(0.35 to 0.50) 0.28(0.21 to 0.38) 0.35(0.29 to 0.42)
3+ 0.20(0.15 to 0.28) 0.15(0.09 to 0.24) 0.15(0.11 to 0.20)
Deprivation (ref: 5 least deprived) 1(most deprived) 0.85(0.74 to 0.97) 0.77(0.62 to 0.97) 0.75(0.65 to 0.87)
2 0.89(0.78 to 1.02) 0.99(0.80 to 1.22) 0.82(0.71 to 0.95)
3 0.94(0.82 to 1.07) 1.05(0.85 to 1.30) 0.98(0.86 to 1.12)
4 0.96(0.84 to 1.10) 1.09(0.89 to 1.33) 0.99(0.86 to 1.13)
Rural/Urban indicator Rural vs Urban 1.07(0.95 to 1.20) 1.10(0.92 to 1.31) 1.01(0.89 to 1.13)
SCN region (ref: London) Cheshire & Merseyside 1.18(0.94 to 1.49) 1.14(0.81 to 1.60) 1.01(0.78 to 1.29)
East Midlands 1.06(0.87 to 1.28) 1.03(0.77 to 1.38) 1.08(0.90 to 1.31)
East of England 1.29(1.08 to 1.55) 1.14(0.87 to 1.50) 1.26(1.05 to 1.51)
Greater Manchester, Lancashire and south Cumbria 1.12(0.91 to 1.36) 0.97(0.72 to 1.31) 1.05(0.86 to 1.29)
North East, north Cumbria, and the Hambleton
& Richmondshire districts of North Yorkshire
1.23(1.00 to 1.51) 1.51(1.11 to 2.04) 1.41(1.14 to 1.73)
South East Coast 1.07(0.88 to 1.32) 1.27(0.96 to 1.69) 1.27(1.05 to 1.55)
South West 1.27(1.05 to 1.54) 1.05(0.77 to 1.43) 1.29(1.06 to 1.57)
Thames Valley 1.20(0.93 to 1.56) 1.17(0.79 to 1.72) 1.08(0.82 to 1.44)
Wessex 1.28(1.03 to 1.58) 1.27(0.91 to 1.77) 1.45(1.16 to 1.80)
West Midlands 1.20(1.00 to 1.43) 0.89(0.65 to 1.20) 1.22(1.02 to 1.46)
Yorkshire & The Humber 0.96(0.79 to 1.17) 1.12(0.84 to 1.48) 1.12(0.93 to 1.35)
*The association is measured by proportion ratios(PRs) and 95 % confidence intervals. PR > 1 indicates a higher probability of hospice death, <1 lower chance of
hospice death, PR = 1 indicates no association. The PRs were derived from modified Poisson regression model, adjusting for the listed variables in the main
analysis but with the omission of the Underlying CoD, number of CYP deaths and number of CYP cancer deaths at SCN region level. -: not estimable
Gao et al. BMC Cancer  (2016) 16:727 Page 11 of 15
Table 7 Factors associated * with hospice death(versus hospital death) in children and young people with cancer, England
1993–2014(N = 12,774)
Variable Value Year of death
1993–2000 2001–2004 2005–2014
Age (ref: 20–24) 0–14 0.37(0.28 to 0.49) 0.59(0.43 to 0.81) 0.85(0.71 to 1.02)
15–19 0.54(0.39 to 0.74) 0.54(0.37 to 0.80) 0.82(0.66 to 1.02)
Gender Male vs female 0.85(0.68 to 1.07) 0.89(0.68 to 1.16) 0.94(0.80 to 1.09)
Underlying cause of death
(ref: Brain & CNS)
Leukaemia 0.21(0.14 to 0.31) 0.25(0.16 to 0.40) 0.17(0.13 to 0.24)
Lymphoma & other haematology 0.26(0.16 to 0.43) 0.16(0.07 to 0.36) 0.29(0.20 to 0.43)
Bone & connective 0.86(0.61 to 1.21) 0.96(0.65 to 1.41) 0.80(0.64 to 1.01)
Renal/Liver/Adrenal including neuroblastoma 0.71(0.43 to 1.16) 0.85(0.49 to 1.48) 0.51(0.37 to 0.70)
Other malignant 0.72(0.53 to 0.97) 0.68(0.46 to 1.00) 0.73(0.59 to 0.90)
Non-cancer 0.09(0.03 to 0.28) 0.05(0.01 to 0.39) 0.04(0.01 to 0.16)
Deprivation (ref: 5 least deprived) 1(most deprived) 0.99(0.71 to 1.39) 0.94(0.60 to 1.48) 0.88(0.68 to 1.13)
2 0.89(0.62 to 1.28) 1.15(0.74 to 1.77) 0.82(0.64 to 1.07)
3 0.70(0.48 to 1.02) 1.18(0.76 to 1.84) 0.97(0.75 to 1.25)
4 0.73(0.50 to 1.07) 1.03(0.65 to 1.64) 0.92(0.70 to 1.20)
Rural/urban indicator Rural vs Urban 0.99(0.70 to 1.39) 1.11(0.75 to 1.64) 0.99(0.78 to 1.24)
SCN region (ref: London) Cheshire & Merseyside 2.09(1.12 to 3.91) 1.27(0.59 to 2.72) 0.99(0.64 to 1.53)
East Midlands 1.01(0.52 to 1.95) 0.78(0.38 to 1.61) 1.00(0.71 to 1.42)
East of England 1.58(0.88 to 2.86) 1.66(0.97 to 2.86) 1.22(0.89 to 1.67)
Greater Manchester, Lancashire and south Cumbria 3.57(2.20 to 5.81) 1.64(0.97 to 2.78) 1.08(0.78 to 1.52)
North East, north Cumbria, and the Hambleton &
Richmondshire districts of North Yorkshire
1.07(0.49 to 2.31) 0.59(0.21 to 1.71) 1.03(0.64 to 1.65)
South East Coast 2.60(1.50 to 4.50) 1.57(0.86 to 2.86) 1.39(1.00 to 1.94)
South West 2.34(1.34 to 4.10) 1.40(0.76 to 2.59) 1.81(1.34 to 2.45)
Thames Valley 1.84(0.82 to 4.15) 0.99(0.40 to 2.45) 1.81(1.25 to 2.62)
Wessex 1.36(0.64 to 2.88) 0.52(0.18 to 1.51) 0.99(0.58 to 1.67)
West Midlands 2.09(1.25 to 3.49) 0.87(0.47 to 1.59) 1.12(0.82 to 1.54)
Yorkshire & The Humber 2.40(1.46 to 3.94) 1.83(1.08 to 3.11) 1.24(0.91 to 1.69)
*The association is measured by proportion ratios(PRs) and 95 % confidence intervals. PR > 1 indicates a higher probability of home death, <1 lower chance of
home death, PR = 1 indicates no association. The PRs were derived from modified Poisson regression model, adjusting for the listed variables in the main analysis
but with the omission of the number of contributing CoDs, the number of CYP deaths and the number of CYP cancer deaths at SCN region level
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Table 8 Factors associated * with hospice death(versus hospital death) in children and young people with cancer, England
1993–2014(N = 12,774)
Variable Value Year of death
1993–2000 2001–2004 2005–2014
Age(ref: 20–24) 0–14 0.44(0.34 to 0.58) 0.77(0.57 to 1.05) 0.95(0.80 to 1.12)
15–19 0.52(0.38 to 0.71) 0.62(0.42 to 0.92) 0.88(0.71 to 1.10)
Gender Male vs female 0.82(0.65 to 1.03) 0.81(0.62 to 1.07) 0.92(0.79 to 1.07)
N. contributing CoDs(ref: 0) 1 0.77(0.61 to 0.98) 0.46(0.33 to 0.65) 0.56(0.46 to 0.67)
2 0.22(0.13 to 0.37) 0.18(0.10 to 0.33) 0.15(0.10 to 0.23)
3+ 0.02(0.00 to 0.17) 0.10(0.04 to 0.24) 0.10(0.06 to 0.17)
Deprivation(ref: 5 least deprived) 1(most deprived) 1.06(0.76 to 1.48) 0.83(0.53 to 1.30) 0.90(0.70 to 1.16)
2 0.92(0.64 to 1.32) 1.07(0.69 to 1.65) 0.85(0.66 to 1.10)
3 0.72(0.49 to 1.05) 1.17(0.75 to 1.81) 1.03(0.80 to 1.32)
4 0.77(0.52 to 1.13) 1.03(0.65 to 1.64) 0.90(0.69 to 1.18)
Rural/Urban indicator Rural vs Urban 1.02(0.73 to 1.45) 1.11(0.76 to 1.64) 0.97(0.77 to 1.22)
SCN region (ref: London) Cheshire & Merseyside 2.02(1.08 to 3.78) 1.12(0.52 to 2.39) 0.86(0.55 to 1.32)
East Midlands 1.02(0.53 to 1.96) 0.69(0.34 to 1.42) 0.90(0.64 to 1.28)
East of England 1.55(0.86 to 2.79) 1.59(0.93 to 2.73) 1.23(0.90 to 1.68)
Greater Manchester, Lancashire and south Cumbria 3.35(2.07 to 5.44) 1.64(0.97 to 2.77) 1.05(0.75 to 1.47)
North East, north Cumbria, and the Hambleton
& Richmondshire districts of North Yorkshire
0.94(0.43 to 2.04) 0.63(0.22 to 1.81) 0.88(0.55 to 1.42)
South East Coast 2.46(1.42 to 4.26) 1.66(0.91 to 3.03) 1.43(1.03 to 1.99)
South West 2.51(1.44 to 4.39) 1.43(0.77 to 2.62) 1.78(1.31 to 2.41)
Thames Valley 1.56(0.69 to 3.51) 0.95(0.39 to 2.34) 1.70(1.17 to 2.47)
Wessex 1.37(0.65 to 2.89) 0.59(0.20 to 1.71) 0.99(0.58 to 1.67)
West Midlands 2.04(1.22 to 3.41) 0.95(0.52 to 1.74) 1.11(0.81 to 1.52)
Yorkshire & The Humber 2.60(1.59 to 4.27) 1.78(1.05 to 3.00) 1.09(0.80 to 1.48)
*The association is measured by proportion ratios(PRs) and 95 % confidence intervals. PR > 1 indicates a higher probability of hospice death, <1 lower chance of
hospice death, PR = 1 indicates no association. The PRs were derived from modified Poisson regression model, adjusting for the listed variables in the main
analysis but with the omission of the Underlying CoD, number of CYP deaths and number of CYP cancer deaths at SCN region level. -: not estimable
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